JPMorgan raises target for Qiagen stock to USD 55.00

Published on 10/16/2026 at 15:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Qiagen revenue was USD 535.04 million in Q2 2026. Qiagen stock costs EUR 41.53 on October 16, 2026, 0.97 percent above the Xetra close.

Target increase shapes valuation

On October 14, 2026, JPMorgan set Qiagen's target at USD 55.00.
Second-quarter revenue reached USD 535.04 million against USD 527.50 million expectations.
Qiagen stock costs EUR 41.53 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST, plus 0.97 percent above the Xetra close of October 15, 2026, EUR 41.13.
Qiagen's price-to-earnings ratio was 23.89 on October 16, 2026.

Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte, klinisches Laborlicht — Qiagen N.V. (NL0012169213) Pipette tropft klare Flüssigkeit in sterile 96-Well-Platte im klinischen Labor, Illustration mit AI erstellt.

On October 14, 2026, JPMorgan raised its Qiagen target from USD 50.00 to USD 55.00 and kept an overweight rating, according to MarketBeat. The new target is 18.66 percent above the NYSE price of USD 46.35 at 3:45 p.m. CEST on October 16, 2026. Qiagen stock was trading at EUR 41.53 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST, plus 0.97 percent versus the Xetra close of October 15, 2026 at EUR 41.13.

Second-quarter revenue beat estimates

Qiagen's second-quarter 2026 revenue reached USD 535.04 million, compared with consensus of USD 527.50 million, according to MarketBeat. That places the reported sales 1.43 percent above the cited estimate and gives the stock a fundamental counterweight to the valuation debate.

Stock remains inside its yearly range

On the NYSE, Qiagen last traded at USD 46.35 on October 16, 2026 at 3:45 p.m. CEST. Its 52-week range was USD 32.53 to USD 57.82, leaving the price 19.84 percent below the high and 42.48 percent above the low. Trading volume stood at 108,630 shares against an average of 2,458,990 shares on the same date.

The euro quotation therefore sits below the upper end of the dollar range while remaining well above its lower boundary. The current position gives the analyst target a clear numerical frame, but it does not establish an investment recommendation.

Valuation and further targets

Qiagen had a market capitalization of USD 9.6 billion, a price-to-earnings ratio of 23.89 and a dividend yield of 0.06 percent as of October 16, 2026. On October 9, 2026, BofA raised its target from USD 49.00 to USD 50.00 and kept a Buy rating, as reported by Markets Insider. That target stands 7.87 percent above the NYSE price of USD 46.35.

Comparison with peers

Qiagen: plus 0.97 percent, P/E 23.89, market capitalization USD 9.6 billion
Thermo Fisher Scientific (NYSE, USD): minus 0.34 percent, P/E 37.47, market capitalization USD 256.7 billion
Danaher (NYSE, USD): minus 0.60 percent, P/E 41.01, market capitalization USD 161.8 billion

Afternoon quote and Xetra close

Qiagen stock was trading at EUR 41.53 at Lang & Schwarz on October 16, 2026 at 3:35 p.m. CEST, plus 0.97 percent versus the Xetra close of October 15, 2026 at EUR 41.13. The Nasdaq quotation was USD 46.35 at 3:45 p.m. CEST on October 16, 2026.

The further course of trading is shown by the continuously updated real-time quote of Qiagen stock.